UW22123
OPEN TO ACCRUAL
PH1 Study of Intra-anally Administered Lopinavir/Ritonavir in Subjects with High-Grade AIN 2/3
UW23016
OPEN TO ACCRUAL
Phase II Liposomal Irinotecan w/ TAS102 & Bevacizumab for Patients w/ mCRC
UW23142
OPEN TO ACCRUAL
PII Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for Early Stage Anal Cancer
EA2222
OPEN TO ACCRUAL
Ph III Study of Systemic Tx +/- Hepatic Arterial Infusion for Unresectable Colorectal Liver Mets
NRGGI008
OPEN TO ACCRUAL
II/III Study of Colon Adjuvant Chemo Based on Eval of Residual Disease (CIRCULATE-NORTH AMERICA)
UW25102
OPEN TO ACCRUAL
Ph2 Neoadj. Dostarlimab (TSR-042) in Stage II/III dMMR Colon Cancer
UW24051
OPEN TO ACCRUAL
Phase 1/2 Basket Study of MK-2870 in GI Cancers
UW25051
OPEN TO ACCRUAL
P1b/2 study of GSK5764227 in previously treated advanced unresectable or metastatic GI solid tumors
UW25112
OPEN TO ACCRUAL
HARMONi-GI3 - P3 Ivonescimab + FOLFOX vs Bevacizumab + FOLFOX for 1st Line mCRC
UWI23-16-01
OPEN TO ACCRUAL
PH2 Study of TPST-1495 in Pts w/ Familial Adenomatous Polyposis (FAP)